Low Dose Interleukin-10 and Anti-IL-1 Antibody in Modulating Intestinal Inflammation

Fioranelli M; Roccia MG

doi:10.4172/ijm.1000I101

ISSN: 2381-8727

International Journal of Inflammation, Cancer and Integrative Therapy

Make the best use of Scientific Research and information from our 700+ peer reviewed, Open Access Journals that operates with the help of 50,000+ Editorial Board Members and esteemed reviewers and 1000+ Scientific associations in Medical, Clinical, Pharmaceutical, Engineering, Technology and Management Fields.

Meet Inspiring Speakers and Experts at our 3000+ Global Conferenceseries Events with over 600+ Conferences, 1200+ Symposiums and 1200+ Workshops on Medical, Pharma, Engineering, Science, Technology and Business

Low Dose Interleukin-10 and Anti-IL-1 Antibody in Modulating Intestinal Inflammation

Fioranelli M^1* and Roccia MG²

¹University B.I.S. Group of institutions, Punjab Technical University, Punjab, India

²Marconi University, Rome, Italy

^*Corresponding Author:: Fioranelli M
University B.I.S. Group of institutions
Punjab Technical University, Punjab, India
Tel: +61 74 9232008
E-mail: massimo.fioranelli@gmail.com

Received date: November 03, 2014; Accepted date: November 20, 2014; Published date: November 22, 2014

Citation: Fioranelli M, Roccia MG (2014) Low Dose Interleukin-10 and Anti-IL-1 Antibody in Modulating Intestinal Inflammation. Interdiscip J Microinflammation 1:i101. doi: 10.4172/2381-8727.1000I101

Copyright: © 2014 Fioranelli M. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Visit for more related articles at International Journal of Inflammation, Cancer and Integrative Therapy

View PDF Download PDF

Clinical Image

This image exemplifies the qualitative evaluation of the structural integrity of the colon which express the Zonula Occludens-1 (ZO-1) tight junctions (TJ) protein. The experiment were performed in order to elucidate the effects of the oral intake of a solution containing interleukin-10 and anti-IL-1 antibody in modulating intestinal inflammation induced by (Dextran Sodium Sulphate) DSS oral administration in a validated experimental murine model. Immunofluorescence staining anti-ZO-1 (in red) in colon samples of different treatment groups highlight the different epithelial barrier TJ structural integrity (arrows).

interdisciplinary-microinflammation-Commons-Attribution-License

Figure 1: This image is reproduced under the terms of the Creative Commons Attribution License.

A significative example for each treatment group is shown: A (UNTR; untreated, hydroalcoholic solution only); B (DSS; DSS 2% plus hydroalcoholic solution); C (DSS+IL-10/anti-IL-1; DSS 2%+interleukin-10 plus anti-IL-1 antibody) Bars: 20 µm. This image clearly shows that mice treated with low doses of interleukin 10 and anti-IL-1 antibody were comparable to untreated mice, in terms of maintenance of an healthy epithelial structure.